22.96 USD
▼-1.74-7.04%
盘后 23.02 0.00%
2026-09-15
市值
$1.19B
市盈率
—
EPS
-8.50
股息率
—
52 周区间
14.85 – 28.38
成交量
158.97K
Beta
—
目标价
37.00
52W 低 14.8552W 高 28.38
价格走势
公司简介
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-...